Notch dysregulation and hidradenitis suppurativa, psoriasis, atopic dermatitis and lichen planus: let's talk about Numb

2019 ◽  
Vol 180 (4) ◽  
pp. 950-951 ◽  
Author(s):  
C. Marasca ◽  
E. Scala ◽  
R. Di Caprio ◽  
A. Raimondo ◽  
S. Cacciapuoti ◽  
...  
Author(s):  
Jonathan W. Rick ◽  
Afsaneh Alavi ◽  
Jennifer L. Hsiao ◽  
Gil Yosipovitch ◽  
Vivian Y. Shi

Cell Cycle ◽  
2020 ◽  
Vol 19 (3) ◽  
pp. 257-267 ◽  
Author(s):  
Elena Campione ◽  
Caterina Lanna ◽  
Laura Diluvio ◽  
Maria Vittoria Cannizzaro ◽  
Sandro Grelli ◽  
...  

2002 ◽  
Vol 15 (2) ◽  
pp. 89-93 ◽  
Author(s):  
C. Feliciani ◽  
A. Tulli

In spite of the drug's toxicity, cyclosporine A (CsA) is largely used in several diseases, including dermatological pathologies, with beneficial results. In dermatology cyclosporin-A reduces the severity of psoriasis symptoms, Bechet's disease, pyoderma gangrenosum, blistering disorders, aftous stomatitis, lichen planus, atopic dermatitis, alopecia and allergic contact dermatitis.


2021 ◽  
Vol 5 (3) ◽  
pp. 203-227
Author(s):  
Justin Marson ◽  
Mark Lebwohl

Objective: To review the literature regarding the efficacy and safety of off-label use of apremilast in combination therapies for psoriasis and psoriatic arthritis and for other currently off-label inflammatory dermatoses. Methods: The Medline database was queried for all relevant articles published between 2014 and 2021 using exploded MeSH terms and keywords pertaining to the following themes: off-label, combination therapy, biologics, biologic therapy, methotrexate, and systemic psoriasis therapy. The Boolean term “AND” was used to find the intersection of these themes with the term “apremilast.” Results: 8 case series and 6 case reports investigated the use of apremilast in combination therapy for psoriasis and psoriatic arthritis. Addition of apremilast improved PASI scores by 31.8-77.4% among case series and 80-100% among case reports with adverse effects primarily consisting of gastrointestinal symptoms. 5 randomized-control trials (RCT), 9 open-label trials, 18 case series, and 30 case reports investigated the use of apremilast for off-label dermatoses. In RCTs, apremilast showed potential efficacy for atopic dermatitis and hidradenitis suppurativa. Open-label trials found apremilast efficacious for atopic dermatitis, allergic contact dermatitis, chronic pruritus, cutaneous sarcoidosis, discoid lupus erythematosus, hidradenitis suppurativa, lichen planus, prurigo nodularis, rosacea, and vitiligo. Limitations: Small sample size and short follow duration up for available randomized-control and open-label trials. Current data from case series/reports potentially limits generalizability of findings. Conclusion: Apremilast's safety profile makes it a potential efficacious, non-biologic systemic agent for monotherapy and combination therapy for a wide range of inflammatory dermatoses.


2020 ◽  
Vol 96 (4) ◽  
pp. 22-31
Author(s):  
Alexander V. Patrushev ◽  
Alexey V. Samtsov ◽  
Vladimir Yu. Nikitin ◽  
Alexey V. Soukharev ◽  
Oksana P. Gumilevskaya ◽  
...  

Background. CLA+T-cell are an important component of skin-associated lymphoid tissue, and thus determine the pathogenesis of many immuno-mediated dermatoses. Aims. Determine the relative number of CLA+T-cell subpopulations in the peripheral blood of patients with psoriasis, lichen planus and atopic dermatitis, as well as assess their impact on the severity of dermatoses. Materials and methods. We examined 82 patients with psoriasis aged 19 to 62 years, 54 patients with lichen planus (LP) aged 18 to 54 years, 44 patients with atopic dermatitis (AD) aged 18 to 44 years, as well as 20 practically healthy individuals aged 18 to 52 years who were admitted to the clinic for the removal of benign skin neoplasms. All patients underwent a standard clinical examination with the determination of indicators that characterize the severity of dermatosis: PASI (Psoriasis Area and Severity Index) for patients with psoriasis, IPSLP (index of prevalence and severity of lichen planus) for patients with lichen planus and SCORAD (Scoring of Atopic Dermatitis) for patients with atopic dermatitis. Defining subpopulations CLA+T-lymphocytes were carried out on a flow cytometer Cytomics FC500 by Beckman Coulter using appropriate combinations of direct monoclonal antibodies and isotopic controls. The groups were compared using the nonparametric Mann Whitney test, and the differences were considered significant at p0,05. To analyze the relationship between the severity of dermatosis and the relative content of subpopulations CLA+T-cells used Spearman's rank correlation coefficient. Results. In patients with psoriasis, a significant increase in the percentage of the total number of T-lymphocytes positive for CLA (CLA+CD3+) and T-helpers positive for CLA (CLA+CD4+) (p=0,002 and 8,5104, respectively), in patients with PL and AD only CLA+CD4+ lymphocytes (p=0,028 and 0,003, respectively). In the progressive period of psoriasis, a direct moderate correlation was found between the circulating subpopulation of cytotoxic T lymphocytes positive for CLA (CLA+CD8+) and the PASI index (rs=0,47; p0,001), in the acute period of AD between the CLA+CD3+ subpopulations and CLA+CD4+ cells and the SCORAD index (rs=0,53; p 0,001 and rs=0,57; p0,001, respectively). In PL, the severity of the course of dermatosis was not accompanied by any significant changes in the CLA-positive T-cell subpopulations. Conclusion. The results of the study confirmed the important role of CLA+T cell subpopulations in the development of chronic dermatoses. In all groups (psoriasis, LP and AD), an increase in the relative number of CLA+CD4+ T-helpers was noted compared with the control group. The relationship between the severity of psoriasis and the relative number of CLA+CD8+ cytotoxic T-lymphocytes, and the severity of AD with CLA+CD3+ and CLA+CD4+ T-helpers is also shown.


2018 ◽  
Vol 138 (9) ◽  
pp. B5
Author(s):  
R. Kaakati ◽  
R.A. Ward ◽  
B. Liu ◽  
C. Green ◽  
T. Jaleel

2015 ◽  
Vol 8 ◽  
pp. A214 ◽  
Author(s):  
Maria Eduarda Pontes Cunha De Castro ◽  
Karine Boufleur ◽  
Phelipe Souza ◽  
Thais Nociti ◽  
Janaina M. Melo ◽  
...  

Author(s):  
A. Gambardella ◽  
G. Calabrese ◽  
E. V. Di Brizzi ◽  
R. Alfano ◽  
G. Argenziano

Sign in / Sign up

Export Citation Format

Share Document